Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
De Novo Lipogenesis in Severity of NAFLD
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
- Trial name
- NCT03683589
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Missouri-Columbia
Non-alcoholic Steatohepatitis
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
- Trial name
- NCT06105060
- Testing
- Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 175 people
- Sponsor
- Beni-Suef University
Non-alcoholic Fatty Liver Disease
Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease
The purpose of this is to analyse human exhaled breath by means of a device called electronic nose(eNose) in patients with non-alcoholic fatty liver disease (NAFLD) as a way to non-invasive assessment of liver disease.This device…
- Trial name
- BEN (NCT02950610)
- Testing
- Breath analysis - electronic signature "Breath-print"
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Fatty Liver
Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
Aim of the research is to assess frequency of MAFLD among patients with acute coronary syndromes (ACS).
- Trial name
- NCT06456970
- Testing
- fibroscan
- Volunteers
- 140 people
- Sponsor
- Assiut University
Fatty Liver, Fatty Liver, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
The purpose of this study is to evaluate diagnostic performance of quantitative ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off values in patients with non-alcoholic fatty liver…
- Trial name
- NCT04462562
- Testing
- Quantitative US (Samsung Medison, RS85A)
- Where
- South Korea
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
NASH, NAFLD
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
The purpose of the KETONASH study is to evaluate, in patients with metabolic-associated fatty liver disease (MAFLD) with non-alcoholic steatohepatitis (NASH) and significant liver fibrosis, the effect of a very low-calorie…
- Conditions
- NASH, NAFLD, Obesity, Liver Fibrosis
- Trial name
- KETONASH (NCT06308757)
- Testing
- Very-low-calorie ketogenic diet (VLCKD) with meal replacements, Mediterranean low-calorie diet (LCD)
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- University of Bologna
Non-Alcoholic Fatty Liver Disease, Obstructive Sleep Apnea
Fatty Liver and Obstructive Sleep Apnea
Non-alcoholic fatty liver disease is associated with obstructive sleep apnea. Abnormalities in liver enzymes can improve following continuous positive airway pressure in patients with obstructive sleep apnea.
- Trial name
- NCT00730873
- Testing
- Continuous positive airway pressure
- Where
- Israel
- Sponsor
- Assaf-Harofeh Medical Center
Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin
The first line approach to NAFLD is currently based on diet and lifestyle modification. Aim of our Unit is to compare the efficacy of two different doses of metformin (1 g/day and 2 g/day) with atorvastatin (20 mg/day) on…
- Trial name
- NCT01544751
- Testing
- Low dose metformin, Metformin, Atorvastatin
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Prof Antonino Belfiore
NAFLD, Obesity
RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) in patients with diabetes (T2DM) is increasing in prevalence and can lead to cirrhosis.
- Conditions
- NAFLD, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT03365531
- Testing
- Alternate Daily Fasting (ADF), Caloric Restriction (CR)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
NAFLD, Osteoporosis
Relation Between NAFLD and BM DENSITY
In general NAFLD is a common denominal for a broad spectrum of damage to the liver, which can be due to hepatocyte injury, inflammatory processes and fibrosis.
- Trial name
- NCT06038253
- Testing
- Fibroscan
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non Alcoholic Fatty Liver
The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
To study the effects of Resveratrol supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Fatty Liver (NAfLD), 50 patients who referred to Gastrointestinal (GI) clinic…
- Trial name
- NCT02030977
- Testing
- Resveratrol
- Volunteers
- 50 people
- Sponsor
- Dr Azita Hekmatdoost
Non-alcoholic Fatty Liver Disease NAFLD, Non-alcoholic Steatohepatitis NASH
Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
The goal of this clinical trial is to assess the efficacy of Empagliflozin versus Statins as monotherapy and polytherapy in non-alcoholic fatty liver disease and non-alcoholic Steatohepatitis.
- Trial name
- NCT07180745
- Testing
- Pioglitazone (PIO), Empagliflozin, Statin (Atorvastatin)
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Badr University
Cirrhosis, Portal Hypertension
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg).
- Conditions
- Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1
- Trial name
- B-REACH (NCT07797101)
- Testing
- Mazdutide injection
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
NAFLD
Genetic-specific Effects of Fructose on Liver Lipogenesis
The primary goal of this study is to identify a set of genotypes that increase the risk for nonalcoholic fatty liver disease (NAFLD) and predispose individuals to increased de novo lipogenesis (DNL) and liver fat accumulation…
- Trial name
- NCT03783195
- Testing
- Sugar drink
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Non-alcoholic Steatohepatitis
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by…
- Trial name
- NCT04722653
- Testing
- NNC0194-0499
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Cardiovascular Diseases, Fatty Liver
Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study
The P-SONAR study is a large, observational, prospective cohort study. The overall aim of the study is to investigate whether plaque burden estimation by 2D ultrasound of the carotid and femoral arteries may enhance…
- Conditions
- Cardiovascular Diseases, Fatty Liver, Atherosclerosis of Femoral Artery, Carotid Artery Plaque
- Trial name
- P-SONAR (NCT06933745)
- Where
- Norway
- Volunteers
- 21,029 people, healthy volunteers welcome
- Sponsor
- University Hospital, Akershus
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Fatty Liver
Metformin in Non-Alcoholic Fatty Liver Disease
The study evaluates the use of the antidiabetic medicine metformin in nonalcoholic fatty liver disease.
- Trial name
- NCT00303537
- Testing
- metformin
- Where
- 4 sites in Norway
- Volunteers
- 90 people
- Sponsor
- University Hospital, Aker
NAFLD
Probiotic Supplementation IN NAFLD Patients
this study aimed to evaluate the effectiveness of Probiotics supplementation (lactobacillus) on NAFLD fibrosis score.
- Trial name
- NCT06074094
- Testing
- Control Test
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Daily Step Count, MASLD
The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD.
The study conducted a health survey among Thai adults in 2022 and found a significant increase in obesity and nonalcoholic fatty liver disease (NAFLD), leading to metabolic-associated steatotic liver disease (MASLD).
- Conditions
- Daily Step Count, MASLD, BMI, Metabolic Syndrome
- Trial name
- NCT06334666
- Testing
- Encourage using pedometer
- Where
- Thailand
- Volunteers
- 86 people
- Sponsor
- Mahidol University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.